OmniComm Systems, Inc. Successfully Integrates Their TrialMaster Electronic Data Capture (EDC) Solution With The National Cancer Institute’s Cancer Data Standards Repository

EDC solution’s integration creates pre-populated global library of NCI developed metadata for customers conducting NCI sponsored clinical trials

FT. LAUDERDALE, FL – May 15, 2007 – /MarketWire/ - OmniComm Systems, Inc. (OTC Bulletin Board: OMCM), one of the fastest growing companies in the EDC marketplace, today announced that it has completed the first commercial integration of an EDC solution with the NCI’s Center for Bioinformatics (NCICB) cancer Data Standards Repository (caDSR). This integration allows customers conducting cancer research to take full advantage of pre-populated global libraries of NCI-developed metadata for their clinical trials.

“This new functionality is just the first step in our adoption of the NCI’s cancer Biomedical Informatics Grid (caBIG™) initiative. Our ability to seamlessly interact with the NCI’s caDSR provides users of our TrialMaster suite of products the ability to quickly and efficiently design and deploy new protocols using a library of standardized common data elements and forms,” said Randy Smith, Chief Technology Officer of OmniComm Systems. “This functionality also allows us to participate to a greater degree with the caBIG community as a whole by providing a means of sharing newly created objects developed in the TrialMaster environment, and then publishing them back to the community using the NCI’s standard curation toolset.”

One of the problems confronting the biomedical data management community today is the multitude of ways in which similar or identical concepts are described. This inconsistency in data descriptors (metadata) makes it very difficult to combine and manage data in order to be able to answer basic questions. The primary goal of the caDSR is to define a comprehensive set of standardized metadata descriptors for cancer research terminology used in information collection and analysis. Various NCI offices and partner organizations have developed the content of the caDSR by registration of data elements based on data standards, data collection forms, databases, clinical applications, data exchange formats, UML models and vocabularies.

Customers using the TrialMaster EDC solution integrated with the NCI’s library of metadata are now able to build clinical trials faster using NCI standards resulting in better information collection and analysis. This will also allow customers to better communicate across the cancer community to better share information using the standards designed by the NCICB and its partners.

About OmniComm

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm’s growing base of satisfied customers is a direct result of the company’s commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm’s client intuitive pricing model allows companies that range from small to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments.

OmniComm ranked in the top 150 as one of the fastest revenue growth technology companies in North America during the last 5 years. In a market overview titled “The Promise of Next-Gen eClinical Trial Software” by Forrester Research, OmniComm was given the highest rating among its competitors for industry middleware. OmniComm Systems Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in California, Maryland, New York, North Carolina and Texas.

Safe Harbor Disclaimer

Statements about OmniComm’s future expectations, including without limitation, future revenues and earnings, plans and objectives for the future operations, future agreements, future economic performance, operations and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. OmniComm intends that such forward-looking statements be subject to the Safe Harbors created thereby. Since these statements involve risks and uncertainties, including but not limited to economic competitive, governmental, contractual and technological factors affecting OmniComm’s operations, markets and profitability, actual results could differ materially and adversely from the expected results.


Back